• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > Glenmark Pharma > December 21, 2010

      Glenmark unit gets FDA nod for felodipine tablets

      Posted Atmarketwatch.com

      MUMBAI (MarketWatch) -- Glenmark Pharmaceuticals Ltd. (532296.BY) Monday said its unit received a final approval from the U.S. Food and Drug Administration for Felodipine extended-release tablets--the generic version of AstraZeneca PLC's (NYSE:AZN) antihypertensive Plendil.

      Glenmark will begin marketing and distribution immediately in the U.S., the company said in a regulatory filing.

      Dec 21, 2010


      Share this Article!

    Back to top^